The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine

Yair Herishanu; Michael Lishner; Yona Kitay-Cohen

doi:10.1097/00001813-200202000-00011

The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine

Yair Herishanu, Michael Lishner, Yona Kitay-Cohen^*

^*Corresponding author for this work

Meir Hospital Sapir Medical Center

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Dacarbazine (DTIC) is commonly used for the treatment of malignant melanoma and Hodgkin's disease. Avery rare complication of this cytotoxic agent is acute vascular hepatic damage, e.g. veno-occlusive disease or Budd-Chiari syndrome. The pathophysiological mechanism involved seems to be an immune reaction. This complication is frequently fatal. We report a patient who developed severe hepatic failure following DTIC treatment who responded favorably to treatment with glucocorticosteroid. [

Original language	English
Pages (from-to)	177-179
Number of pages	3
Journal	Anti-Cancer Drugs
Volume	13
Issue number	2
DOIs	https://doi.org/10.1097/00001813-200202000-00011
State	Published - 2002
Externally published	Yes

Keywords

Dacarbazine
Fulminant hepatitis
Steroids

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00001813-200202000-00011

Cite this

@article{1ab73c73c5564c428bd84e68658c4bd9,

title = "The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine",

abstract = "Dacarbazine (DTIC) is commonly used for the treatment of malignant melanoma and Hodgkin's disease. Avery rare complication of this cytotoxic agent is acute vascular hepatic damage, e.g. veno-occlusive disease or Budd-Chiari syndrome. The pathophysiological mechanism involved seems to be an immune reaction. This complication is frequently fatal. We report a patient who developed severe hepatic failure following DTIC treatment who responded favorably to treatment with glucocorticosteroid. [",

keywords = "Dacarbazine, Fulminant hepatitis, Steroids",

author = "Yair Herishanu and Michael Lishner and Yona Kitay-Cohen",

year = "2002",

doi = "10.1097/00001813-200202000-00011",

language = "אנגלית",

volume = "13",

pages = "177--179",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "2",

}

TY - JOUR

T1 - The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine

AU - Herishanu, Yair

AU - Lishner, Michael

AU - Kitay-Cohen, Yona

PY - 2002

Y1 - 2002

N2 - Dacarbazine (DTIC) is commonly used for the treatment of malignant melanoma and Hodgkin's disease. Avery rare complication of this cytotoxic agent is acute vascular hepatic damage, e.g. veno-occlusive disease or Budd-Chiari syndrome. The pathophysiological mechanism involved seems to be an immune reaction. This complication is frequently fatal. We report a patient who developed severe hepatic failure following DTIC treatment who responded favorably to treatment with glucocorticosteroid. [

AB - Dacarbazine (DTIC) is commonly used for the treatment of malignant melanoma and Hodgkin's disease. Avery rare complication of this cytotoxic agent is acute vascular hepatic damage, e.g. veno-occlusive disease or Budd-Chiari syndrome. The pathophysiological mechanism involved seems to be an immune reaction. This complication is frequently fatal. We report a patient who developed severe hepatic failure following DTIC treatment who responded favorably to treatment with glucocorticosteroid. [

KW - Dacarbazine

KW - Fulminant hepatitis

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=0036188740&partnerID=8YFLogxK

U2 - 10.1097/00001813-200202000-00011

DO - 10.1097/00001813-200202000-00011

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 11901312

AN - SCOPUS:0036188740

SN - 0959-4973

VL - 13

SP - 177

EP - 179

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 2

ER -

The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this